Rationally-selected microbiota (RSM™) Therapies are defined groups of human-derived microbes, carefully selected for their ability to interact with other microbes and the host to drive clinical results.
Finch’s RSM platform employs machine-learning algorithms to mine our unique clinical datasets, reverse engineering successful clinical experience with Full Spectrum Microbiota to identify the key microbes driving patient outcomes. Using machine learning against these data sets enables Finch to determine the most effective therapy (FSM or RSM). RSM therapies target specific, clinically efficacious strains to create a consortium of human-adapted, therapeutic microbes. By enabling the strategic selection of compositions already validated in patients, Finch is introducing a new and rapidly scalable class of microbial therapies.
FIN-524, a microbial cocktail for ulcerative colitis, is our first product candidate based on this philosophy.